Treatment Decision Making in Relapsed/Refractory Multiple Myeloma : Episode 7

Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM

June 19, 2024

By Donna Catamero, ANP-BC, OCN, CCRC
Beth Faiman, PhD

News

Video

Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.

EP: 1.Case Study: 63-Year-Old Man With Multiple Myeloma

EP: 2.Empowering Patients With Myeloma Through Resources

EP: 3.Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma

EP: 4.Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab

EP: 5.Strategies for Discussing Potential Adverse Effects of Talquetamab in MM

EP: 6.Managing Toxicities From Talquetamab in Multiple Myeloma

EP: 7.Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM

EP: 8.Clinical Advice on Caring for Patients Treated With Talquetamab

EP: 9.Insights on Evolving Treatment Strategies for Multiple Myeloma

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos

Image of multiple myeloma cells

Photo of a woman with her hair pulled back in front of a dark blue background

Photo of a woman with her hair in a ponytail in front of a light blue background

Latest Conference Coverage

Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors

PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.